Enhanced Phase II Efforts Paying Dividends, But At A Price, Pfizer Exec Says
Executive Summary
Expanded approaches to Phase II development have reduced Phase III attrition rates, but in doing so, have also created a new set of challenges for pharmaceutical companies, according to Pfizer Senior VP-Science & Technology Peter Corr